Ligand Pharmaceuticals announced that its senior management will participate in several investor conferences throughout May 2026, including virtual and in-person events such as the H.C. Wainwright Royalty Company Conference and the Bank of America Healthcare Conference. These appearances include fireside chats and one-on-one meetings, providing opportunities for investors to engage directly with the company. Ligand is a leading biopharma royalty aggregator with a diverse portfolio, aiming to deliver consistent revenue through strategic partnerships and licensing proprietary technologies. This active investor engagement signals Ligand's commitment to transparency and growth in the biopharmaceutical sector.
Perplexity AI CEO Aravind Srinivas shared lessons from Nvidia's Jensen Huang and Tesla's Elon Musk, highlighting Huang's mindset of running Nvidia as if it could fail within 30 days despite its $5 trillion valuation and advanced technology. Srinivas ...
Meta Platforms introduced an AI-powered feature called "AI Mode" within Facebook Search, which uses Meta's AI model Muse Spark to provide answers from public content rather than traditional search results. This innovation could generate over $10 bill...
Cuprina Holdings shares surged 111.84% intraday following FDA 510(k) clearance for its MEDIFLY Maggots wound care product, the first maggot debridement therapy using Lucilia cuprina species approved in the U.S. The product treats non-healing necrotic...
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
